Miss Shamyla Siddique

Miss Shamyla Siddique

Institute of Cancer and Genomic Sciences
Precision Medicine Centre Industry Trials Lead

Contact details

+44 (0) 121 371 4396
+44 (0) 121 371 4398
Cancer Research UK Clinical Trials Unit (CRCTU)
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Shamyla Siddique is the Precision Medicine Centre Industry Trials Lead at the at the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.


  • MPhil in Evidence-based Pharmacotherapy 2005
  • BSc (Hons) Pharmaceutical Sciences, 2002


Shamyla Siddique graduated with a Pharmaceutical Sciences degree in 2002 and obtained her MPhil from Aston University in 2005. She joined the CRCTU as a Trial Coordinator in September 2005 coordinating a national, multicentre, phase II trial in Acute Myeloid Leukaemia (AML), designed to evaluate the combination of epigenetic therapies in patients with relapsed or refractory disease.

She subsequently coordinated a number of early phase multicenter trials in a variety of haematological malignancies and stem cell transplantation.

She was promoted to Senior Trial Coordinator in 2010 managing of portfolio of haematology trials for which the CRCTU was Sponsor. She has also worked closely with clinical teams at the Queen Elizabeth Hospital and has run trials on behalf on a site and Sponsor. In 2014, she was appointed to Haematology Trials Team Leader and led the Leukaemia and Lymphoma Research’s Trials Acceleration Programme (‘TAP’) with the CRCTU.

Shamyla is currently the Precision Medicine Centre Industry Trials Lead.


Shamyla Siddique has contributed to the design, set-up and/or management of the following trials:

  • VAL/Aza (Acute Myeloid Leukaemia)
  • MiniAlloGlivec (Chronic Myeloid Leukaemia)
  • TRICE (Chronic Myeloid Leukaemia)
  • RICAZA (Acute Myeloid Leukaemia, Allogeneic Stem Cell Transplantation)
  • LenaRIC (Multiple myeloma, Allogeneic Stem Cell Transplantation)
  • HA-1 (Phase I, healthy volunteer vaccination trial)
  • RAvVA (Acute Myeloid Leukaemia)
  • ROMAZA (Acute Myeloid Leukaemia)
  • FIGARO (Acute Myeloid Leukaemia, Allogeneic Stem Cell Transplantation)
  • VIOLA (Acute Myeloid Leukaemia, Allogeneic Stem Cell Transplantation)
  • AZTEC (Graft versus Host Disease)
  • BUBBLE (Multiple Myeloma)

Other activities

  • Member of the National Cancer Research Institute Haemato-Oncology Clinical Studies Group since 2014


Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D., Ivey, A., Virgo, P., Hills, R., McSkeane, T., Arrazi, J., Knapper, S., Brookes, C., Davies, B., Price, A., Wall, K., Griffiths, M., Cavenagh, J., Majeti, R., Weissman, I., Burnett, A., Vyas, P (2012). Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia; Nov 6.

Goodyear, O., Dennis, M., Jilani, N., Loke, J., Siddique, S., Ryan, G., Nunnick, J., Khanum, R., Raghavan, M., Cook, M., Snowden, J., Griffiths, M., Russell, NH., Yin, J., Crawley, C., Cook, G., Vyas, P., Moss, PAH., Malladi, R., Craddock, CF (2012). "Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia." Blood.

Goodyear, O., Agathanggelou A., Novitzky-Basso, I. Siddique, S,. McSkeane, T.Ryan, G.Vyas, P.Cavenagh, J.Stankovic, T.Moss, P.Craddock, C.(2010). "Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia." Blood 116(11): 1908-18.

Olavarria, E., S. Siddique, et al. (2007). "Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia." Blood 110(13): 4614-7.